Professor Gilula Chair of Scripps Research and senior research author Dr. Benjamin Cravatt declare a new proposal of life extension pathway by interfering/suppressing of specific enzyme-associated pathways with particular compounds. In this experiment, C. elegans becomes the best candidates in advantage of observable short lifespan.
The research team used about 100 different compounds as individual treatments and extended the average lifespan of C. elegans for at least 15%. Among those treatments, there is one named JZL184, associated with FAAH-4/2-AG pathway in C. elegans, can make a lifespan extension of 45% in ideal condition.
